Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 3, 2003

View Archived Issues

Effective control of plaque psoriasis achieved with continuous efalizumab

Antitumor effects of irofulven in advanced cancer

Clinical trials confirm the good safety profile of anecorvate acetate

Radiosensitizing effects of GW-572016 and use in combination chemotherapy

Preclinical and clinical antitumor efficacy and clinical safety of Bay-43-9006

R&D highlights from the 3rd Annual Biotech in Europe Investor Forum: Rejuvenon

Beneficial effects of SKI-606 in rat models of stroke

Antiproliferative and cytotoxic effects of aplidine assessed in human cancer cell lines

In vitro efficacy of 2-methoxyestradiol in prostate and pancreatic cancer

New CRF1 antagonists with utility in anxiety and depression

BMS researchers describe new p38 kinase inhibitors and their therapeutic use

New anxiolytic agents prepared and tested by Egis researchers

Roche claims novel alpha1A-adrenoceptor agonists for urinary incontinence and other uses

Novel IBAT inhibitors identified at AstraZeneca

New antibacterial agents described by the former British Biotech (now Vernalis)

Fast track designation for TheraCLEC

Melanotan reduces sunburn injury by increasing melanin density in clinical trial

Celltech to regain rights to CDP-870 from Pfizer

Ganymed acquires ImmuGenics, inlicenses TCR intellectual property

FDA accepts Avastin BLA for priority review

First approval for Erbitux granted by Swiss authorities

IsoTis OrthoBiologics establishes EpiSource subsidiary for wound care portfolio

Neurogen and Merck & Co. target vanilloid receptor through new alliance

Keppra reduces seizures in epileptic patients with brain tumors

P2Y1 receptor antagonists with enhanced potency designed by U.S.-Korean group

R&D highlights from the 3rd Annual Biotech in Europe Investor Forum: Xantos Biomedicine

Antiparkinsonian and antidyskinesia effects of GR-127935, a 5-HT1B/1D receptor antagonist

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...